The Role of Liver Resections for Noncolorectal, Nonneuroendocrine Metastases: Experience With 142 Observed Cases

Ercolani, Giorgio; Grazi, Gian Luca; Ravaioli, Matteo; Ramacciato, Giovanni; Cescon, Matteo; Varotti, Giovanni; Gaudio, Massimo Del; Vetrone, Gaetano; Pinna, Antonio Daniele

doi:10.1245/aso.2005.06.034

Cited by 125 publications

(99 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven studies did not include patients with EHD [18,19,23,25,26,36,40], while stable, isolated bone metastases were accepted in four studies [22,24,37]. Various other EHD was accepted in 9 studies of liver resection, as long as EHD was resectable or stable on therapy [20,21,27,28,29,31,32,35,42], and in four studies of local ablation [45][46][47][48] (table 3).…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Liver resection and local ablation of breast cancer liver metastases – A systematic review

Bergenfeldt

Jensen

Skjoldbye

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Aim : To analyze surgical treatment of breast cancer liver metastases (BCLM) regarding selection criteria, outcome and prognostic parameters.Methods : We searched Embase and Medline for all studies published 1999-2010.Results : Resection was associated with a median survival (MOS) of 20-67 months and 5-year survival of 21-61%. Local ablation also had a favourable outcome; MOS was 30-60 months and and 5-year survival 27-41%. Regarding selection, no specific limits regarding the number and size of BCLM can be given. Features of the primary breast cancer (BC) was not significant for the prognosis. Microscopically radical (R0) resection is a positive prognostic factor, while the effects of disease interval, hormone receptor status and response to preoperative chemotherapy were divergent. The presence of EHD had a negative effect on survival in some studies, but failed to have so in other studies.Conclusions: Surgical therapy may benefit a subset of patients with BCLM. Resection may be indicated, if an RO-resection can be done with a low risk of mortality. Liver resection in the presence of extrahepatic disease remains controversial, while patients with BCLM and bone metastases could possibly be managed differently than other EHD.

show abstract

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

“…Some centres excluded patients with EHD [18,19,23,25,26,36,40], while others accepted patients even with widespread EHD [20,21,27,28,29,31,35,42,]. A third party accepted patients with bone metastases stable on therapy [22,24,37].…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Liver resection and local ablation of breast cancer liver metastases – A systematic review

Bergenfeldt

Jensen

Skjoldbye

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Grandes casuísticas em instituições renomadas e estudos de fatores prognósticos têm sido sistematicamente publicados. Os índices de sobrevida nas últi-mas séries tem se aproximado dos índices publicados nas de metástases CR e tem variado de 24 até 37 % em cinco anos (22,37,38). A sobrevida global de 20 % em cinco anos da presente série, tanto no Grupo 1 (CR) quanto no Grupo 2 (NCRNE) foi similar a de diversas outras séries previamente descritas (1,2,14,37,39).…”

Section: Tabela 5 -Características Dos Sobreviventes Livres De Doençaunclassified

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Costa

Horta

Henriques

et al. 2009

Rev bras. colo-proctol.

View full text Add to dashboard Cite

INTRODUÇÃOAtualmente, a ressecção cirúrgica de metástases hepáticas de etiologia colorretal é a única modalidade com intenção curativa ou de prolongamento da sobrevida. Em séries mais recentemente publicadas, a sobrevida dos pacientes submetidos à sua ressecção completa (R0) tem variado de 25 % até 55 % em cinco anos (1-3). Em contrapartida, quando indivíduos com disseminação hepática são submetidos a tratamento quimioterápico exclusivo, raramente alcançam mais do que três anos de sobrevida (4).

show abstract

“…A few authors have therefore tried to treat metastatic breast cancer with liver resection. Most patients resected have been included in single-center studies reporting the experience with liver resection for metastases from non-colorectal, non-neuroendocrine tumors [12-18]. However, the prognostic factors in such hepatic breast metastases patients have rarely been investigated upon and most of them were focused on survival and the usefulness of liver resection on long-term outcomes measured as median survival time or 5-year overall survival.…”

Section: Introductionmentioning

confidence: 99%

Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: Fifty-one resected patients were reviewed. All patients received adjuvant chemotherapy after resection of the primary tumor. Clinicopathological characteristics and immunohistochemistry expression of estrogen (ER), progesterone (PR), human epidermal growth factor (HER2), or Ki67 were evaluated. Results: The median number of metastases was 2; single metastases were present in 24 (47%) patients. The median tumor diameter was 4 cm. Major hepatectomies were performed in 31 (61%) patients. Postoperative mortality was null. Postoperative morbidity was 13.7%. The 1-, 5-, and 10-year survival rates were 92, 36, and 16% respectively. Eleven (21.6%) patients survived longer than 5 years and 8.9% are alive without recurrence 10 years after surgery. At the univariate analysis, tumor diameter, lymph node status, PR receptor status, and triple positive receptors (ER+/PR+/Her2+) were significantly related to survival. At the multivariate analysis, tumor diameter, PR receptor, and triple negative status were significantly related to the long-term outcome. Conclusion: Liver resection seems to be a safe and effective treatment for metastases from breast cancer, and encouraging long-term survival can be obtained with acceptable risk in selected patients. Tumors less than 5 cm and positive hormone receptor status are the best prognostic factors.

show abstract

The Role of Liver Resections for Noncolorectal, Nonneuroendocrine Metastases: Experience With 142 Observed Cases

Cited by 125 publications

References 23 publications

Liver resection and local ablation of breast cancer liver metastases – A systematic review

Liver resection and local ablation of breast cancer liver metastases – A systematic review

Hepatectomia para o tratamento de metástases colorretais e não-colorretais: análise comparativa em 30 casos operados

Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience

Contact Info

Product

Resources

About